TEL AVIV, Israel, June 29, 2010 /PRNewswire-FirstCall/ —
BSP, which develops and commercializes advanced products for the
non invasive, accurate diagnosis of heart diseases, announced today
that its Add-On product, the HyperQ AD-100 (http://www.bsp.co.il/pdf/HyperQ
AD-100 Pic.pdf), intended for improved diagnostic performance of
Stress ECG, has been granted the European CE conformance mark. The
HyperQ AD-100 product is an add-on system with the HyperQ
technology which is incorporated in parallel to existing standard
stress ECG systems. The integration of the HyperQ AD-100 into
Stress ECG systems enables accurate and sensitive diagnosis of
Ischemic Heart Disease, a leading cause of death in the world.
The unique technology developed by BSP is implemented in a non
invasive manner and does not involve exposure to radiation or other
hazards to patients. It is highly effective in diagnosing sick
people and in ruling out disease in healthy individuals. The HyperQ
AD-100 enables physicians to benefit from the clinical advantages
of the technology without the need to replace their existing
installed Stress ECG system.
BSP CEO, Nissim Greisas: “The
integration of the HyperQ Add-On systems into the vast installed
base of standard Stress ECG systems significantly expands our
potential global market. The worldwide annual stress ECG system
market is estimated at $200M, and the
total standard ECG installed base represents an estimated $800M market for the new product.”
C
‘/>”/>
SOURCE
